Metabolic psychiatry and clinical translation

• Metabolism is already part of brain health, and the urgent question is clinical translation.
• Bret Scher’s path moved from prevention-focused cardiology into low-carb, ketogenic, and wider metabolic health work.
• The Baszucki Group, Metabolic Mind, and the Coalition for Metabolic Health became the setting for scale through research, education, policy, and clinical implementation.

Why Scher left conventional prevention thinking

• Scher did not shift because of one patient; he saw repeated cardiology patients fail lifestyle plans that were hard to sustain and poorly supported in short visits.
• Scher came to see the prevention message itself as part of the problem, not the patients’ willpower.
• Scher also saw a revolving-door pattern in cath labs, hospital units, and cardiac care, with too little upstream prevention.
• Scher had to unlearn the low-fat default and the belief that one healthy diet must be low-fat, grain-centered, and fearful of dietary fat.
• A low-carb, ketogenic, higher-fat, adequate-protein diet can be a healthy option, not an unhealthy diet by definition.

Professional risk and skepticism

• Guideline pressure kept low-fat advice safer professionally, while low-carb care required longer documentation and shared decision-making.
• High LDL in low-carb patients created tension with colleagues, especially when Scher managed those cases conservatively.
• The shift required a different mindset: guidelines matter, but individual metabolic context also matters.

Why the Baszucki work mattered

• The first metabolic psychiatry conference in 2022 gave Scher the clearest view of the people, research, clinical cases, lived experience, and urgency behind the field.
• Jan, Dave, and Matt Baszucki brought urgency from family experience, while clinicians and researchers showed that lives were changing now and that research still needed to catch up.
• The path is to let science lead while helping appropriate patients today under experienced clinical care.

Main barrier to wider adoption

• The largest barrier is still bias and misunderstanding around keto and ketogenic diets.
• Many clinicians still reduce keto to a fad weight-loss diet with bacon and butter, missing its century-long use in epilepsy and its role as a physiologic metabolic intervention.
• Medical training often teaches only ketoacidosis, not nutritional ketosis as a therapeutic condition.
• This creates a double standard in which ketosis is asked to prove long-term safety while the modern high-carbohydrate, ultra-processed, always-fed environment is rarely challenged.
• Better education can move clinicians from reflexive fear toward seeing ketogenic therapy as one metabolic tool.

Ten-year success

• Success would mean metabolic medicine becomes central enough that a dedicated advocacy group is no longer necessary.
• Metabolic psychiatry would sit inside a wider metabolic medicine model alongside cardiometabolic disease, PCOS, diabetes, epilepsy, and cancer-related metabolic work.
• A large collaborative model paper for metabolic psychiatry could mirror the 49-author glioblastoma ketogenic metabolic therapy model.
• Current psychiatric care can reduce episodes for some people, but often does not restore full energy, vitality, and life function.
• Ketogenic and metabolic therapies may add value by helping people regain function, not merely by lowering episode counts.

Medication management and safety

• A major mistake is starting keto, feeling better, and abruptly stopping psychiatric medications.
• Some people have shared strong recovery stories after stopping medications, but others have ended up hospitalized with mania, psychosis, or major depression returning.
• Medication tapering during ketogenic therapy needs research and careful prescriber management.
• Reducing medication burden may matter because antipsychotics and related drugs can carry neurologic, psychiatric, insulin-resistance, weight-gain, and wider metabolic harms.
• Another mistake is entering ketosis too quickly; a slower transition can reduce distress and make adherence easier.

Brain energy and mechanisms

• Brain energy metabolism is underestimated across psychiatry and neurology.
• Severe depression, major depressive disorder, cognitive impairment, and dementia are linked in the conversation to lower brain glucose metabolism.
• Ketone metabolism may remain available when glucose metabolism is impaired, which is why Stephen Cunnane’s work matters here.
• Shifting brain energy first may also influence neurotransmitters, making metabolic care upstream of some neurotransmitter effects.

Clinical use and first-line questions

• Ketogenic therapy should not become a universal first-line psychiatric intervention today.
• Individual patients may use it early when an experienced clinician, patient goals, diagnosis, medication status, safety risks, and monitoring all fit.
• Mild depressive symptoms are one possible scenario where diet quality and a low-carb or ketogenic approach may be reviewed before medication escalation.
• For psychiatric effects, the key markers are glucose and ketones; for overall metabolic health, triglycerides, HDL, fasting insulin, HOMA-IR, body composition, blood pressure, and hsCRP matter.
• Physical capacity can function like a practical biomarker because better energy and ketosis may make later exercise adoption more successful.

Responders, duration, and phenotyping

• Future research needs to understand both responders and non-responders.
• Possible future categories include metabolic depression, metabolic schizophrenia, metabolic bipolar disorder, and metabolic anxiety.
• The challenge is that brain metabolic dysfunction is hard to measure clinically even when peripheral markers look normal.
• For individuals with hard-to-shift depression or bipolar disorder, the practical clinical question can become whether there is a good reason not to try a monitored metabolic therapy.
• The Delphi consensus placed a fair trial around at least three months, while some nutrition trials are too short at four weeks.

Precision metabolic care

• Precision care may include genetics, metabolomics, organic acid testing, B12, omega-3 status, thyroid status, medication effects, and other non-keto drivers of psychiatric symptoms.
• More data can help when patients are not responding, are struggling with nutrition therapy, or want deeper personalization.
• The balance is avoiding overwhelming data that is not actionable.
• The message is not that everyone needs keto; the message is to widen the clinical lens around metabolic and non-metabolic causes.

Research growth and field-building

• The Baszucki Group does not need to control every research direction because outside researchers are already pursuing grants and new disease areas.
• Near-term success would mean research happening broadly, with NIMH and other funding sources reducing dependence on philanthropy.
• ClinicalTrials.gov activity across bipolar disorder, schizophrenia, depression, anorexia, PTSD, Alzheimer’s disease, and related areas is creating momentum.
• Long-term clinical infrastructure could include metabolic psychiatry fellowships and better nutrition education in medical training.
• The Coalition for Metabolic Health aims at the wider education and policy layer of metabolic medicine.

References

• [00:20] Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma — https://doi.org/10.1186/s12916-024-03775-4
• [00:26] Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer’s Disease — https://doi.org/10.3389/fnmol.2016.00053
• [00:40] Awareness and best practices in using ketogenic therapy to treat serious mental illness: a modified Delphi consensus — https://doi.org/10.3389/fnut.2026.1749406